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Objective: Vitamin D is essential for the maintenance of calcium homeostasis and bone mineralization; and low
serum 25-hydroxyvitamin D (s-25-(OH)D) concentrations are associatedwith increased bone turnover. Howev-
er, there is a lack of randomized controlled trials that have investigated the effect of vitaminD treatment on bone
turnover in immigrant populations. We aimed to investigate the effect of 16-week daily vitamin D3 supplemen-
tation on bone formationmarker serumprocollagen type 1 amino-terminal propeptide (P1NP) and bone resorp-
tion marker C-terminal crosslinked telopeptide of type I collagen (CTX).
Design: Double-blind, randomized, placebo-controlled trial.
Setting: Immigrant community centers in Oslo, Norway.
Participants: 251 healthy adults aged 18–50 years with a non-Western immigrant background were recruited.
Intervention: 16 weeks of daily oral supplementation with either 10 μg vitamin D3, 25 μg vitamin D3, or placebo.
Main outcomemeasures:Difference in change during the 16-week intervention between the intervention groups
combined (10 or 25 μg of vitamin D3/day) and placebo, in serum P1NP and serum CTX.
Results: A total of 214 (85%) participants completed the study. S-25-(OH)D increased from 29 nmol/L at baseline
to 49 nmol/L in the intervention group with no signiﬁcant change in the placebo group. However, there was no
difference in change of serum P1NP (mean difference:−1.2 μg/L (95% CI:−5.4, 2.9, P = 0.6)) and serum CTX
(mean difference:−0.005 μg/L (95% CI:−0.03, 0.02, P = 0.7)) between those receiving vitamin D3 supplemen-
tation compared with placebo. The plasma PTH had decreased by a mean of−1.97 pmol/L (95% CI:−2.7,−1.3,
P b 0.0001) in the vitamin D3 group compared to placebo.
Conclusions: Supplementationwith 10 or 25 μg oral vitaminD3 duringwinter and spring for 16weeks did not sig-
niﬁcantly affect serum P1NP and serum CTX, despite increasing s-25(OH)D and decreasing PTH in a healthy im-
migrant population with low baseline vitamin D status.
Trial registration number: NCT01263288.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vitamin D is essential for the maintenance of calcium homeostasis
and bone mineralization, and low serum 25-hydroxyvitamin D (serum
25(OH)D) concentrations might lead to secondary hyperparathyroid-
ism with increased bone resorption and fracture risk (Brot et al., 2001;
Holick and Chen, 2008; Lips, 2001). Bone is metabolically active and is
constantly being repaired and remodeled throughout an individual's
lifetime (Wheater et al., 2013). A reduced rate of bone turnover mayr).
. This is an open access article underlower risk of fracture by maximizing development of peak bone mass
in young adults (Slemenda et al., 1997) and slowing the rate of bone
loss in later life (Riggs et al., 1998). Bone turnovermarkers have a poten-
tial in the prediction of osteoporosis and fracture risk (Vasikaran et al.,
2011). Vitamin D deﬁciency is prevalent worldwide and high preva-
lence of vitamin D insufﬁciency and secondary hyperparathyroidism
(SHPT) among non-Western immigrant populations living in Western
countries has been reported (Islam et al., 2012; Meyer et al., 2004;
Lowe et al., 2010). Recent studies in Norway have shown that in immi-
grants with background from Sub-Sahara Africa, Middle East and South
Asia, nearly 80% had 25(OH)D b50 nmol/L and approximately one-third
had 25(OH)D b25 nmol/L regardless of season (Eggemoen et al., 2013;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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impact of vitamin D deﬁciency on the skeletal homeostasis of immi-
grants is of concern (Roy et al., 2007). High bone turnover in vitamin
D deﬁcient persons was seen in observational studies (Erkal et al.,
2006; Islam et al., 2008; Macdonald et al., 2008). However, the few in-
tervention studies examining the effect of vitamin D supplementation
on bone turnover in population such as Caucasian postmenopausal
women, young adults and immigrants with low vitamin status have
produced mixed results (Grimnes et al., 2012; Macdonald et al., 2013;
Andersen et al., 2008). A one year randomized double-blinded
placebo-controlled intervention with vitamin D3 (10 and 20 μg/d) in
young women and men of Pakistani origin living in Denmark showed
that supplementation increased serum 25(OH)D concentrations and
decreased serum parathyroid hormone (PTH) concentrations but
there was no signiﬁcant effect of the intervention on bone turnover
markers (Andersen et al., 2008). In another randomized trial, four
weeks of daily supplementation with 10 μg vitamin D3 decreased
mean PTH but surprisingly increased tartrate-resistant acid phospha-
tase (s-TRACP, which is a bone resorption marker) concentration in
healthy adults 19–48 years of ethnic Norwegian and Tamil background
(Holvik et al., 2012). Apart from these two RCT's, where one included
only persons with Pakistani background in Denmark and in the other
one the time of supplementation was only 4 weeks, we were unable
to identify any other RCT's that have investigated the effect of vitamin
D treatment on bone turnover in immigrant populations living in devel-
oped countries.
Various bone formation and bone resorption markers have been
suggested for clinical use in the diagnosis and management of a range
of metabolic bone diseases (Wheater et al., 2013). Among bone forma-
tion marker is procollagen type 1 amino-terminal propeptide (P1NP)
which is released into the circulation during bone formation. While
among bone resorption markers include carboxy-terminal cross-
linked telopeptide of type 1 collagen (CTX). CTX is a degradation prod-
uct of type 1 collagen and is released into the circulation during bone re-
sorption (Vasikaran et al., 2011). The Bone Marker Standards Working
Group recommends P1NP and CTX as reference standard markers of
bone formation and resorption (Vasikaran et al., 2011; Stokes et al.,
2011).
We thereforewanted to test the effect of vitaminD supplementation
on bonemarkers in winter time, because bone turnover markers have a
potential in the prediction of osteoporosis and fracture risk.Wehypoth-
esized that the improvement of low vitamin D status in immigrant pop-
ulationwill affect their bonemarkers. The aim of the present study was,
whether 16 weeks of daily vitamin D3 supplementation (10 or 25 μg/d
vs placebo) would affect biochemical markers of bone formation
(serum P1NP) and resorption (serum CTX) in a multi-ethnic immigrant
population in late wintertime.
2. Research design and methods
2.1. Study design and participants
The present work describes predeﬁned additional endpoints of a 16-
week intervention trial with vitamin D supplementation versus placebo
and was performed as previously described in detail (Knutsen et al.,
2014). In brief, healthy men and women, aged 18–50 years, who were
born or had parents born inMiddle East, Africa and South Asia, were re-
cruited through 11 different community centers in Oslo and surround-
ing areas (at latitude 60°N). The exclusion criteria were; regular use of
vitamin D-containing supplements, on-going treatment for vitamin D
deﬁciency, pregnancy, breastfeeding,mal-absorption, use ofmedication
that interfered with vitamin D metabolism (thiazides, anti-epileptics,
prednisolone or hormone replacement therapy), kidney diseases, can-
cer, tuberculosis, sarcoidosis, osteoporosis or recent fracture. All the fe-
male participants were younger than 50 years old (when menopause
normally starts), but they were not asked about menopausal status orcurrent use of oral contraceptions. The same data collection teamvisited
all the centers and performed the baseline and follow-up data collec-
tion. Interpreters were used when necessary, but the majority of the
study participants were able to communicate in Norwegian language.
2.2. Randomization and intervention
Thosewho fulﬁlled the eligibility criteria were randomly assigned to
one of three equally sized intervention groups receiving one tablet per
day containing 25 μg vitamin D3, 10 μg vitamin D3 or placebo. The tab-
lets were similar in color, size and packing. Each participant was given
a box containing 120 tablets (16 week use corresponds to 112 tablets)
at baseline. The tablets were manufactured by Bio Plus Life sciences
PVT LTD, DMA (Bangalore, India), certiﬁed for Good Manufacturing
Practice and the ingredients met the requirements of British
Pharmacopé. If the study subjects had forgotten to take one tablet one
day, they were asked to take two tablets the following day. Participants
were followed up with a short text message twice a week to remind
them to take the tablets. Subjects were advised to maintain their usual
dietary pattern during the 16 week trial period and advised to contact
the study staff by telephone if they had any queries.
2.3. Main outcome variables
The study outcomes were difference in absolute change during the
16 week intervention between the pooled intervention groups (10 or
25 μg of vitamin D3/d) and placebo for bone markers: serum P1NP
(s-P1NP) and serum CTX (s-CTX).
2.4. Random allocation
We chose a computer-generated block randomization to ensure a
good balance of the number in each groupduring the trial and randomly
varying the block size between 3 and 6.
2.5. Blinding
Group allocation was unknown to participants, research staff, inves-
tigators, and data collectors. The tablet boxes were numbered according
to the randomization list by an external pharmacy (the Hospital
Pharmacy at Oslo University Hospital). The group allocation list was
stored at this pharmacy with a copy in a sealed envelope. Each partici-
pant was consecutively numbered and received a pre-packaged tablet
box with the corresponding number.
2.6. Registration
The study was authorized as a clinical trial by the Norwegian Medi-
cine Agency and approved by the Regional Committee for Medical and
Health Research Ethics (study code: 2010/1982). All participants gave
written informed consent.
The study has been registered at EudraCT (2010-021114-36). The
clinical trial was conducted according to the principles of the Declara-
tion of Helsinki and in accordance with national laws. ClinicalTrials.gov
identiﬁer NCT01263288.
2.7. Blood sampling and laboratory assays
Non-fasted venous blood sampleswere collected after 9 am (andbe-
fore 16.00 for themajority of the samples) and at roughly the same time
of day for each participant's visit at baseline and at follow-up. Blood for
serumwas collected in serum-separator gel tubes and centrifuged after
30 min to 2 h, and blood for plasma was collected in EDTA-tubes and
centrifuged within 30 min at room temperature at the study site.
Serum and plasmawere separated and frozen in several aliquots (sepa-
rate tubes for bone markers) at−20 °C for some days and transported
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in Oslo (www.furst.no) until they were analyzed. After the completion
of the study all samples from baseline and follow-up were analyzed in
one batch at Fürst Medical Laboratory (www.furst.no), which is
accredited by the International Organization for Standardization and is
part of vitamin D quality assessment scheme, DEQAS.
Serum 25-hydroxyvitamin D (25(OH)D) was measured using high-
pressure liquid chromatography tandem mass spectrometry (HPLC–
MS–MS), with Waters Acquity UPLC and Waters trippelquadrupole
MS instruments. In house standards at four levels ranging from 25 to
200 nmol/L were calibrated against external MS-standards from Recipe
(Germany), product no. MS7013, traceable to NIST. Deuterized internal
standard 26,27 hexadeuterium labeled 25(OH)D3, purchased from
Synthetica (Norway), was used in the calculation of both 25(OH)D2
and 25(OH)D3. The CV (reproducibility within the laboratory, 4 instru-
ments) for serum 25(OH)D3 was 8% at concentrations of 55.2 nmol/L
and 6% at concentrations of 195.1 nmol/L. The CV for serum 25(OH)D2
was 11% at concentrations of 43.8 nmol/L and 9% at concentrations of
158.5 nmol/L. In the analysis the term 25(OH)D) is used for the sum
of 25(OH)D2 and -D3, but note that the contribution of 25(OH)D2 was
negligible.
Plasma PTH was analyzed with Advia Centaur XP (Siemens HMSD)
with analytical coefﬁcient of variation of 8.2% and reference range of
1.2–8.4 pmol/L. Serum concentrations of calcium (mmol/L), albumin
(g/L), and phosphate were measured using Advia 2400 (Siemens)
and corrected calcium (mmol/L) was calculated as s-calcium− 0.02 ×
(s-albumin− 41.3).
The serum planned for the analyses of bone markers which were
stored in a separate sample series (tubes 1 mL) was transferred on dry
ice (not defrosted allowed to thaw) and stored at−80 °C at Hormone
Laboratory, Oslo University Hospital. CTX and P1NP were analyzed in a
single batch. The bone resorption marker CTX and the bone formation
marker P1NP in serum were measured by electro-chemiluminescenceFig. 1. Flow chart of recruitment, rimmunoassay (ECLIA) (RocheMODULARAnalytics E170 fromRocheDi-
agnostics, Mannheim, Germany). The reference range for women in
childbearing age and men is b0.57 μg/L and total analytical CV was
≤3% for CTX. The reference range for women in childbearing age is
(11–94 μg/L) and for men is (20–91 μg/L) for P1NP and total CV was
≤4%. The Hormone Laboratory participates in Labquality and UK
NEQAS. CTX has a diurnal variation with a maximum peak early in the
morning (05:00–08:00); and declining late in the afternoon.
2.8. Statistical analysis
Sample size calculations based on the expected effect on the primary
end point of the study, muscle strength (Knutsen et al., 2014), indicated
that 210 subjects were required (70 in each group), with recruitment of
250 subjects to account for expected withdrawals (Fig. 1). Statistical
analysis of the data was performed using the IBM SPSS statistical soft-
ware (version 19.0; SPSS Inc., Chicago, IL, USA). For each of the outcome
variables, we calculated the difference in change from baseline to
follow-up between intervention groups and the placebo group using
linear regression analysis. Also the effect on each outcome variable
was adjusted for the respective baseline concentration. P-values b0.05
were considered statistically signiﬁcant. Subgroup analyses by baseline
values of endpoint measures, geographic background, and gender and
intervention dose were also performed.
3. Results
Table 1 summarizes the baseline characteristics of the 214 study par-
ticipants who completed the study. There was no major difference in
subject characteristics between the three groups. The kidney and liver
function tests were normal in the study participants. Also, there was
no signiﬁcant difference in the characteristics of the 37 participants
who did not complete the study compared to those who completedandomization and follow-up.
Table 1
Baseline characteristics for the 214 study subjects who completed the study.a
Characteristics Placebo Vitamin D
(10 μg)
Vitamin D
(25 μg)
N = 71 N = 69 N = 74
Age (years) 39 (7.4) 37 (7.4) 37 (8.2)
Sex, n (%)
Male 15 (21%) 18 (26%) 23 (31%)
Female 56 (79%) 51 (74%) 51 (69%)
BMI (kg/m2) 29.1 (5.2) 27.2 (4.9) 26.6 (5.1)
Ethnic origin (n, %)
South Asia 27 (38%) 25 (36%) 29 (39%)
Middle East & North Africa 12 (17%) 7 (10%) 12 (16%)
Sub-Sahara Africa 32 (45%) 37 (54%) 33 (45%)
Time lived in Norway (years) 13.6 (2–33) 13.2 (1–35) 13.3 (1–29)
Level of education (n, %)
≤10 years 30 (42%) 29 (42%) 29 (39%)
11–13 years 26 (37%) 26 (38%) 26 (35%)
≥14 years 15 (21%) 14 (20%) 19 (26%)
Serum creatinine (μmol/L)b 56.1 (11.6) 56.4 (14.6) 56.6 (12.5)
Serum alanine transaminase (u/L) c 22.3 (12.3) 22.9 (11.9) 21.7 (12.1)
Serum aspartate aminotransferase (u/L)d 20.1 (6.6) 21.0 (6.6) 19.9 (6.7)
Total S-25(OH)D (nmol/L) 29.2 (15.6) 30.7 (20.1) 26.8 (17.1)
Serum 25(OH)D3 (nmol/L) 26.9 (15.1) 27.2 (15.1) 26.8 (17.1)
Serum 25(OH)D2 (nmol/L) 2.3 (8.6) 3.5 (13.5) 0
Serum calcium (mmol/L)e 2.36 (0.10) 2.37 (0.08) 2.37 (0.09)
Serum corrected calcium (mmol/L) 2.30 (0.08) 2.31 (0.06) 2.32 (0.08)
Serum phosphate (mmol/L)e 1.15 (0.15) 1.16 (0.16) 1.13 (0.13)
Plasma PTH (pmol/L)f 8.1 (4.0) 7.1 (3.5) 7.6 (3.8)
Serum P1NP (μg/L) 44.8 (16.0) 47.1 (17.4) 49.0 (26.0)
Serum CTX-1(μg/L) 0.19 (0.10) 0.20 (0.10) 0.19 (0.13)
The mean of s-25(OH)D was 31.3 and 44 nmol/L for males and females respectively.
a Data are mean (standard deviation) unless speciﬁed otherwise.
b None were above the reference range (males 60–105, females 45–90 μmol/L).
c 3 males and 2 females have above the reference limit (men b70, women b45 U/L).
d 1 male and 1 female have above the reference limit (men b45, women b35 U/L).
e Reference range for s-calcium (2.15–2.51 mmol/L) and for s-phosphate (women N18
years: 0.85–1.50 mmol/L and men 18–49 years: 0.75–1.65 mmol/L).
f N = 69 for placebo, 66 for 10 and 74 for 25 μg group due to 5 missing data.
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was 37.6 ± 7.8, and 79% were female. Mean serum 25(OH)D was
28.9 nmol/L (SD 17.6) for the whole group and over 30% had PTH levels
above the upper limit of the reference value (1.2–8.4 pmol/L). ThereTable 2
Effect of intervention with vitamin D supplementationa s-P1NP and s-CTX, s-25(OH)D3, p-PTH
Baselineb After 16 weeksb
Serum 25(OHD) (nmol/L)
Intervention (n = 143) 28.7 (18.6) 48.8 (19.6)
Placebo (n = 71) 29.2 (15.6) 27.5 (13.7)
Serum calcium (mmol/L)
Intervention (n = 143) 2.4 (0.10) 2.37 (0.1)
Placebo (n = 71) 2.4 (0.09) 2.36 (0.1)
Serum corrected calcium (mmol/L)c
Intervention (n = 143) 2.36 (0.08) 2.34 (0.1)
Placebo (n = 71) 2.35 (0.1) 2.34 (0.09)
Serum phosphate (mmol/L)
Intervention (n = 143) 1.14 (0.15) 1.15 (0.16)
Placebo (n = 71) 1.15 (0.14) 1.14 (0.16)
Plasma PTH (pmol/L)
Intervention (n = 140) 7.4 (3.7) 6.1 (2.3)
Placebo (n = 69) 8.1 (4.0) 8.2 (3.9)
Bone turnover markers
Serum P1NP (μg/L)
Intervention (n = 143) 47.9 (22) 46.9 (23)
Placebo (n = 71) 44.8 (16) 45.3 (25)
Serum CTX-1 (μg/L)
Intervention (n = 143) 0.19 (0.11) 0.20 (0.1)
Placebo (n = 71) 0.19 (0.1) 0.20 (0.1)
a Combined 10 and 25 μg doses.
b Adjusted for baseline values.
c Corrected for serum albumin.were 21 (9.8%) persons with serum 25(OH)D below 12.5 nmol and
these had a mean PTH of 9.9 pmol/L (SD 6.5) and a mean calcium of
2.35 mmol/L (SD 0.1). At baseline around 90% and 53% of the partici-
pants had s-25(OH)D levels below 50 nmol/L and 25 nmol/L respective-
ly. There was no correlation between serum25(OH)D values and serum
CTX or serum P1NP at baseline.
3.1. Effects of vitamin D supplementation on serum 25(OH)D, calcium,
albumin-corrected-calcium and plasma phosphate
As previously reported (Knutsen et al., 2014), following the inter-
vention mean serum 25(OH)D had increased by a mean of 17 and
26 nmol/L, respectively for the 10 μg and 25 μg vitamin D3 groups, com-
pared to placebo (Table 2). There was no change in calcium, albumin-
corrected calcium or phosphate as a result of vitamin D supplementa-
tion (Table 2).
3.2. Effects of vitamin D supplementation on bone turnover markers and
plasma PTH
A 16-week supplementation with vitamin D3 (10 or 25 μg com-
bined) compared to placebo had no signiﬁcant effect on serum CTX
and serum P1NP (Table 2), and the difference in percentage change
was −0.7% (95% CI: −7.8 to 6.5, P = 0.8) for P1NP and −6.1% (95%
CI: −25.8 to 13.4, P = 0.5) for s-CTX. As reported earlier (Knutsen
et al., 2014), plasma PTH decreased by a mean of−1.97 pmol/L (95%
CI: −2.7,−1.3, P b 0.0001) with vitamin D3 (10 or 25 μg combined)
compared to placebo.
We also analyzed the effect of the two interventions (10 and 25 μg)
separately, and none of them had a signiﬁcant effect on serum CTX or
serum P1NP (Table 3).
3.3. Additional analyses
There was no difference in the effect of vitamin D supplementation
on serum CTX or serum P1NP when adjusted for geographical back-
ground. Furthermore, there were no signiﬁcant differences between
the combined intervention groups and placebo in any of the end points
after stratiﬁcation by baseline concentration of serum 25(OH)D higher, s-calcium and s-phosphate.
Difference in change (95% CI)b compared to placebo P values
21.3 (16.7, 26.0) b0.0001
−0.005 (−0.03, 0.02) 0.7
−0.007 (−0.03, 0.02) 0.5
0.01 (−0.03, 0.05) 0.5
−1.97 (−2.7,−1.3) b0.0001
−1.2 (−5.4, 2.9) 0.6
−0.005 (−0.03, 0.02) 0.7
Table 3
Effect of intervention with vitamin D supplementationa on serum P1NP, serum CTX, serum 25(OH)D3, plasma PTH, serum calcium and serum phosphate.
Baseline Final (after 16 weeks) Difference in change (95% CI)d
Placebo 10 μg 25 μg Placebo 10 μg 25 μg 10 μg 25 μg
Serum 25(OHD) (nmol/L) 29.2 (15.6) 30.7 (20.1) 26.8 (17.1) 27.5 (13.7) 45.9 (18.7) 51.1 (20.1) 16.7 (11.2, 22.3)‡ 26.1 (20.4, 31.9)‡
Serum calcium (mmol/L) 2.36 (0.1) 2.37 (0.08) 2.37 (0.09) 2.36 (0.11) 2.35 (0.13) 2.38 (0.10) −0.02 (−0.06, 0.01) 0.003 (−0.02, 0.03)
Serum corrected calcium (mmol/L)b 2.30 (0.08) 2.31 (0.06) 2.32 (0.08) 2.34 (0.10) 2.32 (0.11) 2.33 (0.10) −0.02 (−0.05, 0.01) −0.003 (−0.02, 0.02)
Serum phosphate (mmol/L) 1.15 (0.15) 1.16 (0.16) 1.13 (0.13) 1.14 (0.18) 1.15 (0.16) 1.15 (0.16) −0.002 (−0.05, 0.05) 0.04 (−0.01, 0.08)
Plasma PTH (pmol/L)c 8.1 (4.0) 7.1 (3.5) 7.6 (3.8) 8.2 (3.9) 6.1 (2.1) 6.1 (2.5) −1.6 (−2.6,−0.6)‡ −1.97 (−3.0,−0.9)‡
Bone turnover markers
Serum P1NP (μg/L) 44.8 (16.0) 47.1 (17.4) 49.0 (26.0) 46.3 (25.0) 46.6 (17.9) 47.6 (26.5) −1.0 (−6.0, 4.0) −1.5 (−3.0, 2.7)
Serum CTX-1 (μg/L) 0.19 (0.10) 0.20 (0.10) 0.19 (0.13) 0.20 (0.11) 0.20 (0.10) 0.21 (0.11) −0.01 (−0.05, 0.02) −0.004 (−0.04, 0.03)
a 10 and 25 μg doses separately.
b Corrected for serum albumin.
c n = 69 for placebo, 68 for 10 and 74 for 25 μg group.
d Difference in change comparing to placebo.
‡ P b 0.001, PTH difference between placebo in 10 μg group, P = 0.002.
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(Table 4).
3.4. Compliance
Compliance with supplementation was conﬁrmed by counting the
number of tablets in the returned tablet boxes, where 80% had con-
sumed more than 80% of the tablets and 69% had consumed more
than 90% of the tablets.
4. Discussion
In this double blinded randomized controlled trial in a healthy immi-
grant population, daily supplementationwith either 10 μg or 25 μg vita-
min D3 over 16weeks had no effect on the bone turnovermarkers P1NP
and CTX, despite increased serum 25(OH)D and PTH suppression.
Few studies have studied the effect of vitamin D supplementation on
bone markers in immigrant background. Our ﬁndings are in agreement
with the results from a randomized controlled study of Pakistani
immigrants inDenmark (n=199, 13–53 years)whowere supplement-
ed with 10 μg and 20 μg vitamin D3 per day (Andersen et al., 2008). De-
spite the observed increased serum 25(OH)D and decreased PTHTable 4
Effect of vitamin D supplementation on serum P1NP and serum CTX in subgroups.a
Sub-groups Serum P1NP Serum CTX
Effect estimate
(95% CI)
P Effect estimate
(95% CI)
P
25(OH)D (nmol/L)
b25 (n = 113) −3.9 (−11.0, 3.3) 0.3 0.002 (−0.04, 0.04) 0.9
≥25 (n = 101) 1.8 (−2.3, 5.8) 0.4 −0.007 (−0.04, 0.03) 0.7
Gender
Female (n = 158) −0.16 (−3.6, 3.3) 0.9 0.00 (−0.30, 0.29) 0.9
Male (n = 56) −4.9 (−16.7, 6.8) 0.4 −0.04 (−0.1, 0.24) 0.2
Age (years)
b40 (n = 102) −5.5 (−13.0, 2.0) 0.1 −0.01 (−0.05, 0.03) 0.7
≥40 (n = 112) 2.9 (−0.7, 6.7) 0.1 −0.003 (−0.04, 0.03) 0.8
BMI (kg/m2)
b27 (n = 114) −3.7 (−11.6, 4.2) 0.4 0.002 (−0.04, 0.05) 0.9
≥27 (n = 100) −0.2 (−3.9, 3.5) 0.9 −0.02 (−0.05, 0.02) 0.3
Regional backgroundb
South Asia (n = 81) 3.8 (−0.2, 7.7) 0.06 0.006 (−0.03, 0.05) 0.7
Middle East, North
Africa (n = 31)
−1.1 (−6.6, 4.5) 0.7 −0.01 (−0.08, 0.06) 0.8
Africa south for Sahara
(n = 102)
−5.8 (−13.8, 2.3) 0.2 −0.01 (−0.05, 0.03) 0.5
a Effect estimates for each outcome variable are difference in change from baseline to
16 weeks between the combined intervention groups (10 or 25 μg) and the placebo group.
b SouthAsia (Pakistan, India, Afghanistan, Sri Lanka),Middle East, NorthAfrica (Iraq, Syria,
Algeria,Morocco, and Tunisia), andAfrica south for Sahara (Somalia, Ethiopia, Eretria, Ghana,
Gambia).concentrations, the treatment had no effect on any of the bone turnover
markers (serum osteocalcin, urinary pyridinoline and urinary
deoxypyridinoline). In another study in which Tamils and native
Norwegian subjects (n=55, 18–48 years)were given daily supplemen-
tation with 10 μg vitamin D3 in four weeks, there was a decrease in
mean PTH, and an increase in the bone resorption s-TRACP in both
groups. It was suggested that the increase in bone resorption activity,
in spite of the improvement in vitamin D status and corresponding
PTH suppression, was explained partly by the young age of the partici-
pants and by the fact that bone resorption and formation are coupled
processes, so that increased bone formation would be likely to follow
the increase in resorption (Holvik et al., 2012). The age range of our par-
ticipants (18–50 years) and the baseline vitamin D status were similar
to those in the above study but our study had a longer intervention
period.
In studies involving young Caucasian adultswithmarginal vitaminD
deﬁciency, no beneﬁcial effects of vitamin D on bonemarkers have been
observed (Barnes et al., 2006; Seamans et al., 2010; Aloia et al., 2010;
Trautvetter et al., 2014).
Observational studies investigating the relationship between vita-
min D status and bone turnover in South Asian populations residing in
Norway are consistent with our ﬁndings. For example, a comparative
study of Pakistani and Norwegian women living in Oslo (n = 720) re-
ported that hyperparathyroidism coupled with low vitamin D status in
the Pakistani women was not associated with increased bone turnover
and that they had similar bone mineral density (BMD) to the ethnic
Norwegians (Holvik et al., 2006). Skeletal resistance to PTH-stimulated
bone resorption has been described in non-white populations
(Cosman et al., 1997) and may provide a mechanism by which non-
white populations with suboptimal serum 25(OH)D levels retain BMD.
It has been suggested that PTH has a limited role in deﬁning vitamin D
status in individual patients and in guiding vitamin D therapy in clinical
practice (Shibli-Rahhal and Paturi, 2014). However, the clinical impor-
tance of persistent vitamin D deprivation and PTH elevation in immi-
grant men and women should be further explored.
The strengths of this studywere that it was a strictly performed dou-
ble blinded randomized placebo controlled trial, it had good compliance
and relatively high retention. Assessments were performed duringwin-
ter and spring, a timewhen sun exposure has little impact on vitamin D
synthesis, and all blood sampleswere assayed in a single batch. The eth-
nic minorities targeted in our study are known to have generally poor
vitamin D status. The doses used were sufﬁcient to increase the serum
25(OH)D levels, however 50 nmol/Lwas not reached in 43% (25 μg sup-
plementation group) and 62% (10 μg supplementation group). The
study also had some limitations. For instance, although the analyses of
bone markers were pre-planned the study was designed primarily for
muscular strength outcomes. Assuming an SD 17.4 μg/L for P1NP and
0.10 μg/L for CTX, 70 participants per group would have been sufﬁcient
87A.A. Madar et al. / Bone Reports 2 (2015) 82–88to detect differences of 8.3 μg/L in P1NP (equivalent to 17% change); and
0.048 μg/L in CTX (equivalent to 24% change), respectively. Although
larger sample sizes might have provided more power to detect smaller
differences, the non-signiﬁcant changes we observed in this study were
very small (−0.7% for P1NP and−6% for CTX) and of doubtful clinical
relevance.
We did not calculate the dietary intake of calcium of the study sub-
jects and it is possible that thiswas sufﬁcient to suppress bone turnover.
In addition, the duration of the studymight not have been long enough
for participants to achieve sufﬁciently high serum 25(OH)D levels for
long enough to allow detection of signiﬁcant changes in the endpoints.
A longer intervention periodwould have been desirable, but continuing
the trial into summer could have inﬂuenced the results through cutane-
ous synthesis of vitamin D with sun exposure, and might have resulted
in loss to follow-up. Another limitation is that the levels of bonemarkers
especially serum CTX exhibit a circadian rhythm and are inﬂuenced by
time of blood collection and fasting status (Herrmann and Seibel,
2008) and may be attenuated by other factors such as age, gender, eth-
nicity, menopausal status and food intake (Wheater et al., 2013; Clowes
et al., 2002; Jenkins et al., 2013). Therefore, these values need to be
interpreted with caution, keeping in mind that they were obtained
from non-fasting study participants.
However, in order to address these problems, participantswere seen
at roughly the same time of the day and analysis was done in one batch.
There is a lack of age and gender speciﬁc serum reference intervals
for P1NP and CTX in non-white populations, both in their native coun-
tries and for immigrant populations. Collection of data from healthy
non-white populations would be helpful in order to establish appropri-
ate reference rangeswhich can be used to aid interpretationwhenmak-
ing comparisons between different ethnic groups.5. Conclusions
Supplementationwith daily 10 or 25 μg oral vitamin D3 per day dur-
ing winter for 16 weeks did not affect bone turnover markers in a
healthy immigrant population living in Norway, with low baseline vita-
min D status, despite signiﬁcantly decreased PTH levels in both inter-
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